MSCRF awards $1M clinical grant for BRC-OA knee osteoarthritis study

Britecyte’s clinical study—“A Phase 1/2a, Multicenter, Randomized, Controlled, Single-Blind, Dose-Finding Study to Evaluate the Safety and Efficacy of BRC-OA, a Human Adipose Allograft, for Treatment of Knee Osteoarthritis”—was awarded a $1,000,000 Clinical Program Grant from the Maryland Stem Cell Research Fund (MSCRF). The study is designed to evaluate safety and dose-finding for BRC-OA in patients with knee osteoarthritis.

The release as fetched from its publisher. britecyte.com ↗